Embolization of Middle Meningeal Artery in Chronic Subdural Hematoma (ELIMINATE)

July 21, 2023 updated by: Prof. dr. W.Peter Vandertop, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Improving the Outcome of Chronic Subdural Hematoma by Embolization of Middle Meningeal Artery (ELIMINATE)

Chronic subdural hematoma (cSDH) is a common neurological affliction which affects mostly frail and elderly patients. Surgical evacuation by using burr hole craniostomy (BHC) is the most frequently used treatment but carries a recurrence rate varying between 10-30% in the literature. Especially in this frail population re-operation is undesirable. Embolization of the middle meningeal artery is an adjuvant treatment which has been reported in multiple case reports and larger case series, showing a beneficial effect on recurrence rate, reducing it to <5%, without complications.

Objectives: Primary: To evaluate whether additional embolization of the middle meningeal artery after surgery for cSDH reduces the recurrent surgery rate. Secondary: to evaluate whether the use of middle meningeal artery embolization after surgical treatment in symptomatic cSDH patients increases quality of life (SF-36 and the EQ-5D-5L), performance in activities of daily living (AMC Linear Disability Score), functional outcome (mRS), cognitive functioning (MOCA) and reduces mortality, occurrence of complications, recurrence rate, size and volume of the hematoma, neurological impairment (mNIHSS, Markwalder score) and the use of care and health-related costs (iMCQ and iPCQ).

Study design: Multicenter, randomized controlled open-label superiority trial. Study population: Patients diagnosed with a cSDH who require surgery. Intervention: The intervention group will receive embolization in addition to standard surgical treatment. The control group will receive surgery only.

Main study endpoint: The number of patients who require reoperation within 24 weeks after the intervention.

Symptomatic cSDH patients will undergo peri-operative embolization of the middle meningeal artery until 72 hours after surgical treatment. Complications are monitored during hospital admission and follow-up. Radiological and clinical follow-up is at eight, 16 and 24 weeks post-intervention with a CT-scan of the head and assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ. Standard care after surgery entails outpatient follow-up with on average two CT-scans, indicated by clinical signs and symptoms.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Chronic subdural hematoma A chronic subdural hematoma (cSDH) is a bleeding of the bridging veins between the dura mater and the arachnoid.

Subdural hematomas are one of the most common forms of hemorrhage affecting mostly elderly people. The estimated incidence in Western countries is 8.1 per 100,000 per year in patients aged 65 years or older, but increases to 58/100,000/year for those aged 70 years or older. With the elderly population growing, the incidence of cSDH is expected to double by 2030. CSDH presents itself as an heterogeneous disease with various symptoms. Most common are gait disturbances, focal deficits, headaches and hemiparesis. Risk factors for occurrence are chronic alcoholism, male gender and anticoagulation and antiplatelet therapy. CSDH is a challenging disease of which the pathophysiology is not completely clear. Even though cSDH initially arises due to tearing of the bridging veins, its chronicity likely has an arterial origin. At first a subdural hematoma forms after a (minor) head trauma. The hematoma persists due to failure of the reparative and absorbing mechanisms. The current hypothesis states that the inability of the human body to heal the hematoma is due to increased neovascularization in the subdural membrane of the hematoma. This leads to repeated micro hemorrhages and further increase in fibrinolytic activity, which makes the body unable to stop recurrent microbleeds. Repeated micro hemorrhages are caused by collateral blood vessels originating from the middle meningeal artery. The correlation between the cycle of re-bleeding and fibrinolysis, and reabsorption of the subdural collection will determine whether the cSDH will resolve, persist or enlarge.

Treatment options The first treatment option for mildly symptomatic cSDH is a conservative 'wait-and-scan' approach in which the patient is followed with CT-scans and outpatient clinic visits. The majority (75%) of these conservatively managed patients however, eventually still require surgery (own data). Medical treatment is a second non-surgical treatment option currently being studied in large RCTs, for instance with steroids (dexamethasone), mannitol, tranexamic acid (TORCH-study), statins and ACE-inhibitors.

Surgical treatment is most frequently used in symptomatic patients with a cSDH as surgery provides instant decompression of the brain and rapid relief of (life-threatening) symptoms. However, surgery is costly and in these often frail patients with multi-morbidity, surgery comes with significant risks for future cognitive functioning and therefore loss of independence. Furthermore, recurrence rates after surgery range from 9-30%, resulting in frequent re-operations. Therefore, the optimal treatment for cSDH remains a 'burning clinical question' for which neurologists and neurosurgeons do not have evidence-based answers. Multiple studies have described successful treatment with embolization of the middle meningeal artery as an adjunct to surgical evacuation. The goal of embolization is to devascularize the subdural membranes to a sufficient extent such that the balance is shifted from the continued rebleeding and accumulation of blood products towards reabsorption of the subdural effusion. The use of embolization in cSDH patients was first reported in 2000, and since then multiple case reports, case series and cohort studies have been published investigating the safety and effectiveness. The largest cohort study compared 72 patients with embolization (as sole treatment or with surgical treatment combined) to 469 (retrospectively) non-surgical treated patients. In this study no complications were reported and only one patient needed repeat surgery. A relatively large case series of 60 patients was reported, again with no complications and a success rate of 92% (patients who were able to avoid surgery). Recent systematic reviews on middle meningeal artery embolization highlight the lower recurrence and complication rate in all embolization cases (<5% and 0%, respectively). Nevertheless, these results are based on non-randomized studies with moderate quality and a small sample size. The effect of embolization as an adjunct to surgical evacuation has never been evaluated in a randomized controlled trial.

In conclusion, although surgery is still the primary treatment option for the majority of patients with cSDH, it carries a significant risk of additional morbidity and mortality and has a relatively high risk of treatment failure. In the aging population, comorbidities are more frequent and the risk of peri-operative complications is acknowledged, limiting a favorable clinical outcome. Middle meningeal artery embolization appears to be a promising adjunct therapy to surgery, which might reduce the necessity for repeat surgical treatment and improve clinical outcome is this vulnerable patient group.

Study Type

Interventional

Enrollment (Estimated)

170

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Netherlands
      • Amsterdam, Netherlands, 1100 DD
        • Recruiting
        • Amsterdam University Medical Centers

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

48 years to 88 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • · CT-confirmed diagnosis of chronic Subdural Hematoma;

    • Primary surgical treatment based on clinical symptoms (progressive neurological deficits).

Exclusion Criteria:

  • · Significant contraindication to angiography (eg. allergy for contrast);

    • Structural causes for subdural hemorrhage, e.g. arachnoid cysts, cortical vascular malformations and a history of cranial surgery in the previous 365 days;
    • Inability to obtain informed consent from the patient or legal representative (when the patient has a depressed level of consciousness), including language barrier;
    • Monocular blindness on contralateral side of the hematoma;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standard Care: burr hole surgery
Patients who have had burr hole evacuation for symptomatic chronic subdural hematomas will be followed in the outpatient clinic after hospital discharge at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
Active Comparator: embolisation middle meningeal artery
Besides standard treatment those patient who are allotted to the intervention group will receive embolization of the middle meningeal artery until 72 hours after burr hole evacuation. After hospital discharge follow-up is at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
Procedure: embolization of the middle meningeal artery
The embolization procedure will be as follows: first femoral artery access will be obtained by using a 5 French micropuncture kit and common carotid and external carotid angiography is performed using a standard 5 French diagnostic catheter. A microcatheter is then advanced selectively under roadmap guidance into the middle meningeal artery (MMA), and MMA angiography is performed to evaluate for potential dangerous anastomoses such as the orbital branch to the ophthalmic artery. Embolization is performed using polyvinyl alcohol particles (100 microns in diameter) under blank fluoroscopic roadmap while carefully avoiding reflux. Particles are infused until lack of anterograde flow into the MMA branches is demonstrated on angiography, and the catheters are removed [31]. The procedure is performed under local anesthesia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reoperation
Time Frame: 8 weeks after discharge.
Number of patients who require a reoperation for recurrent cSDH
8 weeks after discharge.
Reoperation
Time Frame: 16 weeks after discharge.
Number of patients who require a reoperation for recurrent cSDH
16 weeks after discharge.
Reoperation
Time Frame: 24 weeks after discharge.
Number of patients who require a reoperation for recurrent cSDH
24 weeks after discharge.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hematoma volume reduction
Time Frame: 8 weeks after discharge.
hematoma volumes are measured on CT-scan of the head and compared to pre-operative volume
8 weeks after discharge.
Hematoma volume reduction
Time Frame: 16 weeks after discharge.
hematoma volumes are measured on CT-scan of the head and compared to pre-operative volume
16 weeks after discharge.
Hematoma volume reduction
Time Frame: 24 weeks after discharge.
hematoma volumes are measured on CT-scan of the head and compared to pre-operative volume
24 weeks after discharge.
Complications
Time Frame: 8 weeks after discharge.
Number of complications will be monitored
8 weeks after discharge.
Complications
Time Frame: 16 weeks after discharge.
Number of complications will be monitored
16 weeks after discharge.
Complications
Time Frame: 24 weeks after discharge.
Number of complications will be monitored
24 weeks after discharge.
modified National Institute Health Stroke Scale score
Time Frame: 8 weeks after discharge.
Neurological impairment measurement using mNIHSS; score 0 (no symptoms) to 31 (severe stroke)
8 weeks after discharge.
modified National Institute Health Stroke Scale score
Time Frame: 16 weeks after discharge.
Neurological impairment measurement using mNIHSS; score 0 (no symptoms) to 31 (severe stroke)
16 weeks after discharge.
modified Rankin Scale score
Time Frame: 24 weeks after discharge.
functional outcome measurement using mRS; score 0 (no symptoms) to 5 (severe handicap)
24 weeks after discharge.
modified National Institute Health Stroke Scale score
Time Frame: 24 weeks after discharge.
Neurological impairment measurement using mNIHSS; score 0 (no symptoms) to 31 (severe stroke)
24 weeks after discharge.
Montreal Cognitive Assessment
Time Frame: 8 weeks after discharge.
cognitive functioning measurement using MOCA; score 0 (severe deficit to 30 (no deficit)
8 weeks after discharge.
Montreal Cognitive Assessment
Time Frame: 16 weeks after discharge.
cognitive functioning measurement using MOCA; score 0 (severe deficit to 30 (no deficit)
16 weeks after discharge.
Montreal Cognitive Assessment
Time Frame: 24 weeks after discharge.
cognitive functioning measurement using MOCA; score 0 (severe deficit to 30 (no deficit)
24 weeks after discharge.
mortality
Time Frame: 8 weeks after discharge.
mortality rate
8 weeks after discharge.
mortality
Time Frame: 16 weeks after discharge.
mortality rate
16 weeks after discharge.
mortality
Time Frame: 246 weeks after discharge.
mortality rate
246 weeks after discharge.
Activities of Daily Living Scale
Time Frame: at 24 weeks after discharge.
Assesses functional independence, generally in stroke patients; score 0 (totally dependent to 100 (completely independent)
at 24 weeks after discharge.
Short Form Health Survey
Time Frame: at 24 weeks after discharge.
Quality of life measurement using a 36-item, patient-reported survey of patient health; consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
at 24 weeks after discharge.
EuroQol (EQ-5D-5L) questionnaire
Time Frame: at 24 weeks after discharge.
Quality of life measurement:The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
at 24 weeks after discharge.
Medical Consumption questionnaire
Time Frame: at 24 weeks after discharge.
Care- and health-related costs measurement using a generic instrument for measuring medical costs. The iMCQ includes questions related to frequently occurring contacts with health care providers and can be complemented with extra questions that are relevant for specific study populations.
at 24 weeks after discharge.
Productivity Cost Questionnaire
Time Frame: at 24 weeks after discharge.
Care- and health-related costs measurement using a generic instrument for measuring medical costs
at 24 weeks after discharge.
Markwalder grading scale score
Time Frame: at eight weeks after discharge
Neurological impairment measurement using the Markwalder grading scale; score 0 (neurologically normal) to 4 (Comatose with absent motor responses to painful stimuli, decerebrate or decorticate posturing)
at eight weeks after discharge
Markwalder grading scale score
Time Frame: at 16 weeks after discharge
Neurological impairment measurement using the Markwalder grading scale; score 0 (neurologically normal) to 4 (Comatose with absent motor responses to painful stimuli, decerebrate or decorticate posturing)
at 16 weeks after discharge
Markwalder grading scale score
Time Frame: at 24 weeks after discharge
Neurological impairment measurement using the Markwalder grading scale; score 0 (neurologically normal) to 4 (Comatose with absent motor responses to painful stimuli, decerebrate or decorticate posturing)
at 24 weeks after discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Investigators

  • Study Chair: William P. Vandertop, MD PhD, Amsterdam Universities Medical Centers

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 10, 2020

Primary Completion (Estimated)

July 1, 2025

Study Completion (Estimated)

October 1, 2025

Study Registration Dates

First Submitted

August 7, 2020

First Submitted That Met QC Criteria

August 11, 2020

First Posted (Actual)

August 13, 2020

Study Record Updates

Last Update Posted (Estimated)

July 24, 2023

Last Update Submitted That Met QC Criteria

July 21, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AMC Eliminate

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Subdural Hematomas

Clinical Trials on embolization of the middle meningeal artery

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe